Weitz & Luxenberg is investigating complaints from farmers who say that their crops have been harmed by the weed killer dicamba, which is sold by…Read More
For people injured by defective drugs or medical devices, Weitz & Luxenberg’s experienced team of attorneys, led by Paul J. Pennock and Ellen Relkin, can help discuss your legal options.Speak to an Attorney Now
Drugs and medical devices must gain approval from the U.S. Food & Drug Administration (FDA) to be sold in the U.S. However, approval does not guarantee a drug or medical device is safe. In fact, a defect in the product, incomplete labeling, or insufficient warnings can cause physical, psychological, or emotional injury. The manufacturer, not the FDA, is responsible for ensuring that its label is updated to protect the public safety.
Weitz & Luxenberg is committed to holding drug and device makers and marketers accountable for the harm they cause. For 30 years, we have strived to help innocent victims harmed by defective drugs and defective medical devices obtain the justice that they deserve.
Weitz & Luxenberg has nearly 100 attorneys ready to fight for you, many of whom have decades of experience, and all are at Weitz & Luxenberg because they care about the clients we represent.
Paul J. Pennock has been Chair of the Drug and Medical Device Litigation practice group at Weitz & Luxenberg for two decades. Widely considered one of the best and most skilled plaintiff litigators in the country, Pennock has helped recover more than a billion dollars for our clients. He has been national co-lead counsel on major litigations and has served on numerous Plaintiff Steering Committees. Get In Contact >
Ellen Relkin has represented thousands of people injured by defective medical products, with a recent focus on failed metal-on-metal hip implants and modular hip implants and SGLT2 Inhibitor medications Invokana and Farxiga She’s been consistently named as a Super Lawyer in New York and New Jersey, and she serves in many court-appointed leadership roles. Get In Contact >
A surgical procedure that’s gone wrong; prolonged pain and weakness; an inability to return to work or resume your normal activities — these are all potential complications, among many others, that can occur as a result of dangerous drugs or medical devices. Such defective medical products can have a negative impact on your life and the lives of your loved ones. In many cases, the injuries caused by certain drugs or devices are more debilitating than the condition that first led to their use. Fortunately, injured consumers can obtain exceptional representation with Weitz & Luxenberg.
The FDA defines the term “drug” as a substance:
The FDA defines the term “device” as an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including a component part or accessory:
No law firm can restore anyone’s life or health, but Weitz & Luxenberg can help seek compensation through exceptional legal representation for harm caused by drugs and devices, including but not limited to:
If you were hurt by a drug or device, or your loved one was harmed by or died from a medical product, let us know, so that we can potentially help.
A nationally recognized personal injury and mass tort law firm, Weitz & Luxenberg has won $17 billion in settlements and verdicts.*
You and your staff are to be commended. I have never been involved in a litigation before and had no idea what would happen. You relieved that tension.
I’m pleased with the results Weitz & Luxenberg achieved for me in my recently settled case. I was suing a hip-replacement company that tried to act like they did nothing wrong. But the fact is they… Read More
My Weitz & Luxenberg legal team led by Mr. Peter Samberg obtained for me twice as much money as I thought I would be able to receive from my lawsuit. I was very pleased about that. Read More
* Past performance is no guarantee of future results. The Actos verdict was reduced to approximately $38 million by the trial court on October 27, 2014. The settlements in which Weitz& Luxenberg played leadership roles included patients not represented by Weitz & Luxenberg.